Interferon regulatory factor 5 is critical for the development of lupus in MRL/lpr mice

Arthritis and Rheumatism

Volumn 63, Issue 3, 2011, Pages 738-748

  Tada, Yoshifumi ^a   Kondo, Seiji ^b   Aoki, Shigehisa ^a   Koarada, Syuichi ^a   Inoue, Hisako ^a   Suematsu, Rie ^a   Ohta, Akihide ^a   Mak, Tak W ^c   Nagasawa, Kohei ^a  

^a SAGA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; CELL NUCLEUS ANTIGEN; CYTOKINE; INTERFERON REGULATORY FACTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL POPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; GENE TARGETING; GLOMERULONEPHRITIS; IMMUNE RESPONSE; IMMUNE SYSTEM; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; SPLEEN; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOANTIBODIES; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLOMERULONEPHRITIS; HOMOZYGOTE; HUMANS; INTERFERON REGULATORY FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED MRL LPR; MICE, KNOCKOUT; RISK FACTORS; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9;

EID: 79953718368     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30183     Document Type: Article

References (47)

1. Kotzin BL. Systemic lupus erythematosus. Cell 1996;85:303-6. (Pubitemid 26160701)
2. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999;10:413-24. (Pubitemid 29068083)
3. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979;301:5-8. (Pubitemid 9226519)
4. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982;25: 401-6. (Pubitemid 12158948)
5. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610-5. (Pubitemid 36297546)
6. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, et al. Coordinate over-expression of interferon-α-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004;50: 3958-67. (Pubitemid 39643944)
7. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005;76:528-37. (Pubitemid 40250533)
8. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006;38:550-5.
9. Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR, Baechler EC, et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci USA 2007;104:6758-63. (Pubitemid 47175574)
10. Shin HD, Sung YK, Choi CB, Lee SO, Lee HW, Bae SC. Replication of the genetic effects of IFN regulatory factor 5 (IRF5) on systemic lupus erythematosus in a Korean population. Arthritis Res Ther 2007;9:R32.
11. Reddy MV, Velazquez-Cruz R, Baca V, Lima G, Granados J, Orozco L, et al. Genetic association of IRF5 with SLE in Mexicans: higher frequency of the risk haplotype and its homozygozity than Europeans. Hum Genet 2007;121:721-7. (Pubitemid 46916971)
12. Kawasaki A, Kyogoku C, Ohashi J, Miyashita R, Hikami K, Kusaoi M, et al. Association of IRF5 polymorphisms with systemic lupus erythematosus in a Japanese population. Arthritis Rheum 2008; 58:826-34.
13. Honda K, Taniguchi T. IRFs: master regulators of signaling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006;6:644-58. (Pubitemid 44298214)
14. Barnes BJ, Kellum MJ, Field AE, Pitha PM. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol 202;22:5721-40.
15. Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, Pitha PM, et al. The interferon regulatory factor, IRF5, is a central mediator of Toll-like receptor 7 signaling. J Biol Chem 2005;280: 17005-12. (Pubitemid 41389162)
16. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 2005;434:243-9. (Pubitemid 40388058)
17. Paun A, Reinert JT, Jiang Z, Medin C, Balkhi MY, Fitzgerald KA, et al. Functional characterization of murine interferon regulatory factor 5 (IRF-5) and its role in the innate antiviral response. J Biol Chem 2008;283:14295-308.
18. Kyogoku C, Tsuchiya N. A compass that points to lupus: genetic studies on type I interferon pathway. Genes Immun 2007;8:445-5.
19. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991;9:243-69.
20. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985;37:269-390. (Pubitemid 15093080)
21. Andrews BS, Eisenberg RA, Theofilopoulos AN, Izui S, Wilson CB, McConahey PJ, et al. Spontaneous murine lupus-like syndromes: clinical and immunopathological manifestations in several strains. J Exp Med 1978;148:1198-215. (Pubitemid 9053639)
22. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356: 314-7.
23. Watson ML, Rao JK, Gilkeson GS, Ruiz P, Eicher EM, Pisetsky DS, et al. Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestation and renal disease-modifying loci. J Exp Med 1992;176:1645-56.
24. Tada Y, Koarada S, Tomiyoshi Y, Morito F, Mitamura M, Haruta Y, et al. Role of inducible costimulator in the development of lupus in MRL/lpr mice. Clin Immunol 2006;120:179-88. (Pubitemid 44080674)
25. lpr mice. J Immunol 2004;173:5312-8. (Pubitemid 39387816)
26. Tada Y, Nagasawa K, Ho A, Morito F, Koarada S, Ushiyama O, et al. Role of the costimulatory molecule CD28 in the development of lupus in MRL/lpr mice. J Immunol 1999;163:3153-9. (Pubitemid 29431814)
27. lpr mice. J Immunol 1998;161:494-503. (Pubitemid 28285560)
28. Yokoyama H, Kreft B, Kelley VR. Biphasic increase in circulating and renal TNF-α in MRL-lpr mice with differing regulatory mechanisms. Kidney Int 1995;47:122-30.
29. lpr mice. Kidney Int 1998;53:1631-41. (Pubitemid 28243746)
30. Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and-independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004;199:1631-40. (Pubitemid 38821996)
31. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005;115: 407-17. (Pubitemid 40385482)
32. Savarese E, Chae O, Trowitzsch S, Weber G, Kastner B, Akira S, et al. U1 small nuclear ribonucleroprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 2006;107:3229-34.
33. Ledbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Schlom-chik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-7. (Pubitemid 34406754)
34. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK. Association of the IRF5 risk haplotype with high serum interferon-α activity in systemic lupus erythematosus patients. Arthritis Rheum 2008;58:2481-7.
35. Yasuda K, Richez C, Maciaszek JW, Agrawal N, Akira S, Marshak-Rothstein A, et al. Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J Immunol 2007;178:6876-85. (Pubitemid 46847413)
36. Yanai H, Chen H, Inuzuka T, Kondo S, Mak TW, Takaoka A, et al. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc Natl Acad Sci USA 2007;104:3402-7. (Pubitemid 46364171)
37. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Schlomchik MJ. Toll-like receptor 9 controls anti-DNA auto-antibody production in murine lupus. J Exp Med 2005;202:321-31. (Pubitemid 41043827)
38. Wu X, Peng SL. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum 2006;54:336-42. (Pubitemid 43122217)
39. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Schlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoanti-body specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006;25:417-28. (Pubitemid 44354217)
40. Nickerson KM, Christensen SR, Shupe J, Kashgarian M, Kim D, Elkon K, et al. TLR9 regulates TLR7-and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol 2010;184:1840-8.
41. Kono DH, Haraldsson MK, Lawson BR, Pollard KM, Koh YT, Du X, et al. Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proc Natl Acad Sci USA 2009;106:12061-66.
42. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004;13:339-43. (Pubitemid 38788493)
43. McHale JF, Harari OA, Marshall D, Haskard DO. TNF-α and IL-1 sequentially induce endothelial ICAM-1 and VCAM-1 expression in MRL/lpr lupus-prone mice. J Immunol 1999;163:3993-4000. (Pubitemid 29450929)
44. Zhou T, Edwards CK III, Yang P, Wang Z, Bluethmann H, Mountz JD. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J Immunol 1996;156:2661-5. (Pubitemid 126660608)
45. Hron JD, Peng SL. Type I IFN protects against murine lupus. J Immunol 2004;173:2134-42. (Pubitemid 38971652)
46. -/- mouse models of systemic lupus erythematosus. J Immunol 2010;184: 796-806.
47. Savitsky DA, Yanai H, Tamura T, Taniguchi T, Honda K. Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus. Proc Natl Acad Sci U S A 2010;107:10154-9.